Indivior (INDV) Competitors $11.66 +0.12 (+1.04%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends INDV vs. NUVL, LEGN, IONS, BPMC, ELAN, CYTK, CORT, TGTX, VKTX, and TLXShould you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Nuvalent (NUVL), Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Corcept Therapeutics (CORT), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical preparations" industry. Indivior vs. Nuvalent Legend Biotech Ionis Pharmaceuticals Blueprint Medicines Elanco Animal Health Cytokinetics Corcept Therapeutics TG Therapeutics Viking Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Indivior (NASDAQ:INDV) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation. Which has more volatility & risk, INDV or NUVL? Indivior has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Do analysts recommend INDV or NUVL? Indivior currently has a consensus price target of $16.00, indicating a potential upside of 37.22%. Nuvalent has a consensus price target of $112.60, indicating a potential upside of 33.70%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvalent 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85 Which has preferable valuation and earnings, INDV or NUVL? Indivior has higher revenue and earnings than Nuvalent. Indivior is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndivior$1.18B1.36$2M-$0.04-291.50NuvalentN/AN/A-$126.22M-$3.47-24.27 Does the MarketBeat Community favor INDV or NUVL? Nuvalent received 32 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 76.92% of users gave Nuvalent an outperform vote. CompanyUnderperformOutperformIndiviorOutperform Votes8100.00% Underperform VotesNo VotesNuvalentOutperform Votes4076.92% Underperform Votes1223.08% Is INDV or NUVL more profitable? Nuvalent has a net margin of 0.00% compared to Indivior's net margin of -0.17%. Nuvalent's return on equity of -28.63% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Indivior-0.17% -351.08% 15.24% Nuvalent N/A -28.63%-27.15% Do institutionals and insiders believe in INDV or NUVL? 60.3% of Indivior shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer INDV or NUVL? In the previous week, Nuvalent had 10 more articles in the media than Indivior. MarketBeat recorded 11 mentions for Nuvalent and 1 mentions for Indivior. Indivior's average media sentiment score of 1.67 beat Nuvalent's score of 1.08 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nuvalent 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNuvalent beats Indivior on 10 of the 18 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Indivior News Delivered to You Automatically Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDV vs. The Competition Export to ExcelMetricIndiviorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-291.4310.5989.9717.18Price / Sales1.36195.801,116.21116.99Price / Cash6.4057.1642.8937.86Price / Book31.515.094.784.78Net Income$2M$151.83M$120.23M$225.60M7 Day Performance0.78%-2.13%-1.92%-1.23%1 Month Performance8.36%-3.10%11.49%3.36%1 Year Performance-25.73%11.54%30.57%16.60% Indivior Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDVIndivior2.456 of 5 stars$11.66+1.0%$16.00+37.2%-22.3%$1.61B$1.18B-291.431,164Positive NewsNUVLNuvalent2.1944 of 5 stars$86.53-0.4%$112.60+30.1%+16.9%$6.15BN/A-25.0340Insider TradeNews CoveragePositive NewsLEGNLegend Biotech1.548 of 5 stars$33.61-4.3%$81.54+142.6%-43.2%$6.14B$520.18M-36.971,800IONSIonis Pharmaceuticals4.4164 of 5 stars$38.62+5.5%$60.65+57.0%-26.3%$6.10B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageBPMCBlueprint Medicines2.5701 of 5 stars$95.23+2.2%$122.11+28.2%+7.2%$6.05B$434.42M-45.28640Insider TradeELANElanco Animal Health3.7742 of 5 stars$12.20+0.8%$16.75+37.3%-17.0%$6.03B$4.45B30.259,300CYTKCytokinetics4.1372 of 5 stars$49.22+1.2%$83.93+70.5%+36.8%$5.81B$3.22M-9.04250Analyst ForecastCORTCorcept Therapeutics4.9121 of 5 stars$55.01-0.7%$65.25+18.6%+66.5%$5.76B$482.38M43.97300Analyst RevisionTGTXTG Therapeutics4.3127 of 5 stars$34.81+8.7%$40.67+16.8%+87.1%$5.42B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2931 of 5 stars$48.02+2.1%$106.75+122.3%+139.8%$5.35BN/A-51.5620Analyst ForecastTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$15.76+1.0%$21.00+33.2%N/A$5.28BN/A0.00N/ANews CoverageGap Down Related Companies and Tools Related Companies NUVL Alternatives LEGN Alternatives IONS Alternatives BPMC Alternatives ELAN Alternatives CYTK Alternatives CORT Alternatives TGTX Alternatives VKTX Alternatives TLX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INDV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
